title: Oncogramme, a new individualized tumor response testing method: application to colon cancer.
abstract: Colon cancer is the second leading cause of cancer-related death in industrialized countries. Many anti-cancer researches are consequently performed and individualized tumor response testing (ITRT) methods are now used to individualize patient chemotherapeutic administrations. Then, a new ITRT method, Oncogramme, was developed for colon cancer. Colon tumor fragments from different patients were dissociated and seeded in a defined culture medium. Cell preparation process as well as culture medium allowed high cell viability and a good primary culture success rate. After treatment of isolated tumoral cells by chemotherapeutics alone or in combination, cytotoxicity was determined by cell death assay allowing the Oncogramme establishment, which was validated by statistical analysis. Indeed, significant results were obtained such as different profile for each patient's cells with various drugs, and variability between patient's cells in the response to each drug. Procedure described here to obtain the Oncogramme is a new, fast and technically reliable ITRT method applied to colon cancer. For an individualized cancer treatment use, this test should be further validated by a phase I clinical trial.
authors.affiliation: Oncomedics, Faculté de Médecine, 2 rue du Docteur Marcland, 87027, Limoges, France, e.loum@oncomedics.com.
authors.forename: Elodie
authors.initials: E
authors.lastname: Loum
authors.forename: Stephanie
authors.initials: S
authors.lastname: Giraud
authors.forename: Barbara
authors.initials: B
authors.lastname: Bessette
authors.forename: Serge
authors.initials: S
authors.lastname: Battu
authors.forename: Muriel
authors.initials: M
authors.lastname: Mathonnet
authors.forename: Christophe
authors.initials: C
authors.lastname: Lautrette
references.citation: J Clin Oncol. 2007 May 1;25(13):1670-6
references.pmid: 17470860
references.citation: Cancer Res. 1981 May;41(5):1751-6
references.pmid: 7214343
references.citation: J Natl Cancer Inst. 1981 Jun;66(6):981-8
references.pmid: 7017216
references.citation: Tech Coloproctol. 2004 Nov;8 Suppl 1:s167-9
references.pmid: 15655611
references.citation: Clin Cancer Res. 1997 May;3(5):741-7
references.pmid: 9815744
references.citation: Blood. 1990 Dec 1;76(11):2327-36
references.pmid: 2257305
references.citation: Anticancer Drugs. 1998 Jan;9(1):51-7
references.pmid: 9491792
references.citation: CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30
references.pmid: 15661684
references.citation: Am J Obstet Gynecol. 2003 Nov;189(5):1301-7
references.pmid: 14634558
references.citation: Cells Tissues Organs. 2007;185(1-3):20-8
references.pmid: 17587804
references.citation: Eur J Cancer. 1997 May;33(6):960-6
references.pmid: 9291821
references.citation: Eur J Cancer. 2010 Mar;46(4):765-81
references.pmid: 20116997
references.citation: Cancer Surv. 1993;16:15-29
references.pmid: 8348534
references.citation: Tumori. 2001 Jan-Feb;87(1 Suppl 1):S85
references.pmid: 11300039
references.citation: Anticancer Res. 1990 Sep-Oct;10(5A):1189-200
references.pmid: 2241098
references.citation: Mol Toxicol. 1989 Oct-Dec;2(4):271-84
references.pmid: 2490980
references.citation: J Clin Oncol. 2004 Jan 15;22(2):229-37
references.pmid: 14657227
references.citation: Anticancer Res. 1998 Sep-Oct;18(5A):3579-83
references.pmid: 9858942
references.citation: J Clin Oncol. 1992 Jun;10(6):896-903
references.pmid: 1534121
references.citation: Gastric Cancer. 2006;9(2):82-7
references.pmid: 16767362
references.citation: Leuk Lymphoma. 2003 May;44(5):783-9
references.pmid: 12802914
references.citation: Cancer Metastasis Rev. 1984;3(3):177-91
references.pmid: 6437669